Equity Profile

NTRA

Natera, Inc.

Health CareBiotechnology$39.1B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Natera, Inc. is a biotechnology company focused on genetic testing and diagnostics, particularly in the areas of prenatal testing and oncology....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and helps investors gauge the company's financial health.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is crucial for long-term sustainability.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NTRA Q2-2026 Earnings Preview

Context

Company Snapshot

Natera, Inc. is a biotechnology company focused on genetic testing and diagnostics, particularly in the areas of prenatal testing and oncology. As part of the health care sector, Natera plays a vital role in advancing personalized medicine and improving patient outcomes through its innovative testing solutions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-25.11%

Avg Stock Reaction

+1.61%

Last Quarter Recap

In Q1-2026, Natera reported an EPS of -$0.60, which was worse than the expected -$0.53, resulting in a 12.78% negative surprise. Despite this, the stock rose by 2.20% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Natera's upcoming earnings are mixed, with investors closely watching for any signs of improvement in profitability and revenue growth. The company's recent history of missing EPS estimates could weigh on sentiment.

Bull Case

If Natera can report better-than-expected EPS and show strong revenue growth, it could boost investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company continues to miss EPS estimates and shows weak revenue growth, it may lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for this quarter?

Given the company's recent history of EPS misses, the actual EPS will be crucial in determining market reaction and investor sentiment.

How much growth in test volumes will Natera report?

Test volume growth is a key indicator of demand for Natera's services and will be closely monitored to assess the company's market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Natera's potential for recovery, particularly in test volume growth, which could surprise positively this quarter.

Supporting Evidence

The company's recent focus on expanding its test offerings could lead to higher-than-expected demand.

Despite recent misses, the stock has shown resilience with positive reactions following earnings, indicating underlying investor support.

Key Risk

If test volume growth exceeds expectations, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical for Natera as it seeks to regain investor confidence after a series of disappointing earnings.

Bull Confirmed If

An EPS of -$0.50 or better, along with a significant increase in test volume growth, would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.60 and stagnant or declining test volumes would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.15%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move for Natera's stock following the earnings report, suggesting that investors expect volatility.

Options are pricing ±14.2% while NTRA has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.3%

Calls (19K)P/C Ratio: 0.17Puts (226K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Natera beats expectations, history suggests the stock could rise by around 1.81%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to muted reactions, as management commentary could drive uncertainty in the stock's direction.

Miss

If the company misses expectations, history suggests a potential decline of about 1.41%, which could further dampen investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new test offerings and their expected impact on revenue.
2Management's commentary on competitive positioning in the genetic testing market.
3Insights into customer acquisition strategies and their effectiveness.
4Any changes in guidance for future quarters based on current performance.
5Details on cost management initiatives and their impact on profitability.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Natera, Inc. is a biotechnology company focused on genetic testing and diagnostics, particularly in the areas of prenatal testing and oncology....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and helps investors gauge the company's financial health.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is crucial for long-term sustainability.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NTRA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-25.11%

Avg Stock Reaction

+1.61%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Natera can report better-than-expected EPS and show strong revenue growth, it could boost investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company continues to miss EPS estimates and shows weak revenue growth, it may lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for this quarter?

Given the company's recent history of EPS misses, the actual EPS will be crucial in determining market reaction and investor sentiment.

How much growth in test volumes will Natera report?

Test volume growth is a key indicator of demand for Natera's services and will be closely monitored to assess the company's market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Natera's potential for recovery, particularly in test volume growth, which could surprise positively this quarter.

Supporting Evidence

The company's recent focus on expanding its test offerings could lead to higher-than-expected demand.

Despite recent misses, the stock has shown resilience with positive reactions following earnings, indicating underlying investor support.

Key Risk

If test volume growth exceeds expectations, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical for Natera as it seeks to regain investor confidence after a series of disappointing earnings.

Bull Confirmed If

An EPS of -$0.50 or better, along with a significant increase in test volume growth, would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.60 and stagnant or declining test volumes would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.15%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move for Natera's stock following the earnings report, suggesting that investors expect volatility.

Options are pricing ±14.2% while NTRA has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.3%

Calls (19K)P/C Ratio: 0.17Puts (226K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Natera beats expectations, history suggests the stock could rise by around 1.81%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to muted reactions, as management commentary could drive uncertainty in the stock's direction.

Miss

If the company misses expectations, history suggests a potential decline of about 1.41%, which could further dampen investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new test offerings and their expected impact on revenue.
2Management's commentary on competitive positioning in the genetic testing market.
3Insights into customer acquisition strategies and their effectiveness.
4Any changes in guidance for future quarters based on current performance.
5Details on cost management initiatives and their impact on profitability.